Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Orthopaedics
  • Orthopaedics News
  • Dotinurad Outperforms...

Dotinurad Outperforms Febuxostat in Lowering Uric Acid Levels in Chinese Gout Patients: Phase 3 Trial

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-10-14T20:00:26+05:30  |  Updated On 14 Oct 2025 8:00 PM IST
Dotinurad Outperforms Febuxostat in Lowering Uric Acid Levels in Chinese Gout Patients: Phase 3 Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

China: A phase 3 clinical trial has shown that dotinurad, a selective urate reabsorption inhibitor, is more effective than febuxostat in reducing serum uric acid levels in Chinese patients with gout while maintaining a comparable safety profile. The findings, published in Arthritis & Rheumatology, suggest that dotinurad may provide a new treatment option for individuals struggling with gout management.

The study was led by Dr. Jia Sun from the Department of Endocrinology, Zhujiang Hospital of Southern Medical University, Guangzhou, and colleagues. The team aimed to directly compare the urate-lowering efficacy and safety of dotinurad against febuxostat, one of the most widely used therapies for gout.
In this multicenter, randomized, double-blind, parallel-group trial, 451 patients with gout were recruited and randomly assigned in a 1:1 ratio to receive either oral dotinurad or febuxostat. Of these, 441 participants were included in the full analysis set. Patients were followed over 24 weeks, with the primary endpoint being the proportion achieving target serum uric acid levels of ≤6.0 mg/dL.
The study led to the following notable findings:
  • At week 24, 73.6% of patients receiving dotinurad 4 mg/day achieved the target serum urate level compared to 38.1% in the febuxostat 40 mg/day group.
  • The adjusted difference of 35.9% was statistically significant, confirming the superiority of dotinurad.
  • At week 12, dotinurad 2 mg/day was found to be noninferior to febuxostat 40 mg/day, with responder rates of 55.5% versus 50.5%.
  • Treatment-emergent adverse events (TEAEs) were reported at similar rates in both groups, suggesting dotinurad is generally well tolerated.
The researchers acknowledged several limitations. The use of the LOCF (last observation carried forward) method in the primary analysis may have introduced some bias due to missing data, though sensitivity analyses supported the robustness of the results. The relatively short study duration restricted the ability to assess long-term outcomes such as recurrent gout flares or the development of tophi, which were not evaluated in this trial. Furthermore, flare prophylaxis was not permitted, leaving uncertainty about flare incidence in real-world practice.
Another limitation was the absence of a direct comparison between dotinurad 4 mg/day and the higher febuxostat dose of 80 mg/day, commonly prescribed in Western countries when 40 mg/day proves insufficient. Additionally, the study population was largely male and relatively young, limiting the generalizability of findings across sexes and age groups.
"Despite these caveats, the trial adds important evidence supporting dotinurad as an effective and safe urate-lowering agent in Chinese patients with gout. Longer and broader studies will be necessary to evaluate its impact on long-term disease outcomes and its comparative efficacy against higher doses of febuxostat," the authors concluded.
Reference:
Sun, J., Wang, Y., Cheng, Y., Guo, D., Hu, J., Liu, D., Gao, Z., Li, C., Lu, Y., Kong, X., Liu, Y., Jiang, Z., Yi, B., Zhang, H., Xu, B., Yu, S., Kokan, R., Ishikawa, K., Kawakatsu, M., . . . Zhang, Z. Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. Arthritis & Rheumatology. https://doi.org/10.1002/art.43261
Arthritis & Rheumatologydotinuradfebuxostatgout
Source : Arthritis & Rheumatology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    EASD 2025: First-Ever Guidelines Released to Address Diabetes Distress

    EASD 2025: First-Ever Guidelines Released to Address Diabetes Distress

    PRO-ACT Study Compares Topical Minoxidil 5% with PRCT vs Plain Minoxidil 5% in Androgenetic Alopecia-Combination Shows Superior Efficacy

    PRO-ACT Study Compares Topical Minoxidil 5% with PRCT vs Plain Minoxidil 5% in Androgenetic...

    DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin-  Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology  Settings

    DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV...

    Indias Unique CV Risk Profile: How to Decode the Role of Aspirin?

    India's Unique CV Risk Profile: How to Decode the Role of Aspirin?

    Vildagliptin-Dapagliflozin FDC Effective in High CV Risk Indian T2DM Patients: Findings from Latest DAa-ViNCI Study

    Vildagliptin-Dapagliflozin FDC Effective in High CV Risk Indian T2DM Patients: Findings from Latest...

    View All

    Journal Club Today

    EASD 2025: First-Ever Guidelines Released to Address Diabetes Distress

    EASD 2025: First-Ever Guidelines Released to Address Diabetes Distress

    View All

    Health News Today

    Health Bulletin 14/October/2025

    Health Bulletin 14/October/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok